JPRN-UMIN000002298未知2 期
Randomized phaze II clinical trial of intermittent docetaxel plus prednisone for the treatment of hormone-refractory prostate cancer - Phase II intermittent docetaxel for hormone-refractory prostate cancer
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1. active infection 2. history of previous radiotherapy to pelvis, severe comorbidity, history of any other malignancy which includes synchronal double cancer 3. chest Xray shows obvious interstitial pneumonia and pulmonary fibrosis 4. patients who have been included in another clinical trial less than 6 months before agreement of this trial 5. patients who are judged as unsuitable for the trial by the doctor in charge
研究者
相似试验
尚未招募
2 期
To determine whether the intensification of treatment in the form of chemotherapy and EGFR TKI gefitinib) combination increases survival among a â??high riskâ?? sub population of patients with lung cancer who have an EGFR mutatioCTRI/2022/02/040621CMC Vellore
进行中（未招募）
1 期
A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer.ocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-ESPuma Biotechnology Inc.126
进行中（未招募）
1 期
A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer.ocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-PTPuma Biotechnology Inc.126
进行中（未招募）
1 期
A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer. - NSABP FB-7 STUDYocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-ITPuma Biotechnology Inc.141
已完成
2 期
A phase IIb randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients BLING IISevere Sepsis in the Intensive Care patientInfection - Studies of infection and infectious agentsBlood - Other blood disordersACTRN12612000138886HMRC442